Welcome to Investors' Day

June 23, 2022

©TERUMO CORPORATION

1

Table of Contents

  • Executive Management Committee Introduction
  • Strategic Vision and Growth Strategy
  • Business Overview
  • Plasma Innovations Ecosystem
  • Wrap Up

©TERUMO CORPORATION

2

Executive Management Committee

We have invested in talent to support our aspirations

Chetan Makam

Veerle d'Haenens

Delara Motlagh

Cynthia Hougum

John Tanner

Gene Stellon

Blood Center

Therapeutic

Cell Therapy

Plasma Innovations

Strategy,

Research &

Solutions

Systems

Technologies

Market Access &

Development

Innovation

Cindy Ng

Chris Williams

Bon Lopez

Rebecca Bortolotti

Rusty Spinney

Global Sales &

Global

Human Resources

General Counsel &

Chief Financial

Services

Manufacturing

Government Affairs

Officer

  • Recruited seasoned leaders to create market- driven innovation and unleash enterprise synergies
  • Promoted proven internal talent to build business ecosystems for next stage of growth
  • Extended our depth in Government Affairs, Market Access and Regulatory

©TERUMO CORPORATION

3

Strategic Vision

Our Aspiration

  • Provide compelling and accessible innovations globally that unlock the power of blood and cells to improve patient outcomes and serve unmet medical needs

How this will be achieved

  • By inspiring and engaging our associates, we will optimize quality and deliver world-class solutions, earning customer loyalty and setting industry standards

GS26 Financial Aspiration

  • Sales : Near Double Digit Growth
  • Adjusted Operating Profit: Beyond 20%

©TERUMO CORPORATION

4

Returned to Growth - Revenue and Profit

Historical Operating Performance

US$ in Millions

4.2%

4.7%

4.0%

8.8%

0.2%

0.0%

$872

$986

$1032

$1073

$944

$946

$872

49%

49%

49%

48%

51%

49%

Adjusted

14%

15%

18%

17%

14%

14%

FY16

FY17

FY18

FY19

FY20

FY21

FY 16-19 at actual FX rates; FY 20-21 at FY 21 Plan FX rates

Transformational Shifts

  • Shifted investment to growth areas
    • Diversified beyond equipment and blood
    • Built infrastructure in growth geographies
    • Sharpened strategic focus in services
  • Modernize infrastructure
    • Optimized manufacturing footprint
    • Implemented one global quality system
    • Adopted SFDC and Service Max globally
  • Continue investing ~12% of sales in R&D

©TERUMO CORPORATION

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Terumo Corporation published this content on 23 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2022 08:04:02 UTC.